Ashok Balasubramanyam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8183224/publications.pdf

Version: 2024-02-01

98 papers	2,882 citations	201385 27 h-index	189595 50 g-index
101 all docs	101 docs citations	101 times ranked	3232 citing authors

#	Article	IF	Citations
1	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished Î²-Cell Function in Patients With Type 2 Diabetes in the GRADE Study. Diabetes, 2022, 71, 1261-1271.	0.3	11
2	Covid-19: A new cause of â€œprovokedâ€•A-Î²+ Ketosis-Prone Diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108147.	1.2	3
3	Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up. Journal of General Internal Medicine, 2022, 37, 3062-3069.	1.3	8
4	Mechanistic Investigation of GHS-R Mediated Glucose-Stimulated Insulin Secretion in Pancreatic Islets. Biomolecules, 2022, 12, 407.	1.8	3
5	Optimizing maturityâ€onset diabetes of the young detection in a pediatric diabetes population. Pediatric Diabetes, 2022, 23, 447-456.	1.2	3
6	Abstract 009: Differential Effect Of An Intensive Lifestyle Intervention On Risk For Cardiovascular Events According To Baseline Level Of Glycated Hemoglobin. Circulation, 2022, 145, .	1.6	1
7	Heightened levels of plasma growth differentiation factor 15 in men living with HIV. Physiological Reports, 2022, 10, e15293.	0.7	5
8	Association of Baseline Characteristics With Insulin Sensitivity and Î²-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	4.3	16
9	Defining and Classifying New Subgroups of Diabetes. Annual Review of Medicine, 2021, 72, 63-74.	5.0	9
10	Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Diabetes Care, 2021, 44, 1203-1210.	4.3	22
11	Islet autoantibody <scp>types mark</scp> differential clinical characteristics at diagnosis of pediatric type 1 diabetes. Pediatric Diabetes, 2021, 22, 882-888.	1.2	3
12	Serum Branch Chain Amino Acids (BCAAs) Are Elevated Due to Decreased Catabolism in Patients With Ketosis-Prone Diabetes at the Time of Presentation With DKA. Journal of the Endocrine Society, 2021, 5, A430-A430.	0.1	0
13	Metabolomics Profiling of Patients With Aâˆ’Î²+ Ketosis-Prone Diabetes During Diabetic Ketoacidosis. Diabetes, 2021, 70, 1898-1909.	0.3	8
14	Toward an Improved Classification of Type 2 Diabetes: Lessons From Research into the Heterogeneity of a Complex Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4822-e4833.	1.8	8
15	HIV-1 Viral Protein R Couples Metabolic Inflexibility With White Adipose Tissue Thermogenesis. Diabetes, 2021, 70, 2014-2025.	0.3	3
16	Exome sequencing in children with clinically suspected <scp>maturityâ€onset</scp> diabetes of the young. Pediatric Diabetes, 2021, 22, 960-968.	1.2	6
17	Pancreatic Differentiation of Stem Cells Reveals Pathogenesis of a Syndrome of Ketosis-Prone Diabetes. Diabetes, 2021, 70, 2419-2429.	0.3	1
18	Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genetics in Medicine, 2021, 23, 2404-2414.	1.1	14

#	Article	IF	Citations
19	Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Research and Care, 2021, 9, e002320.	1.2	8
20	The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathyâ€"The GRADE study. Journal of Diabetes and Its Complications, 2021, 35, 108047.	1.2	3
21	Type 2 diabetes in prepubertal children. Pediatric Diabetes, 2021, 22, 946-950.	1.2	21
22	The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia, 2020, 63, 2040-2048.	2.9	86
23	The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4393-e4406.	1.8	4
24	Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1295-1306.	1.6	67
25	Abstract 16: Association of Baseline & Longitudinal Changes in Fitness & Body Mass Index With Risk of Heart Failure in Individuals With Type 2 Diabetes Mellitus: An Analysis From the Look Ahead Trial. Circulation, 2020, 141, .	1.6	1
26	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2019, 21, 682-690.	2.4	4
27	Lymphocytes upregulate CD36 in adipose tissue and liver. Adipocyte, 2019, 8, 154-163.	1.3	15
28	Response to Comment on Mulukutla et al. Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of â€œA+â€•Subtypes of Ketosis-Prone Diabetes. Diabetes Care 2018;41:2637â€“2640. Diabetes Care, 2019, 42, e82-e83.	4.3	0
29	Evaluation and management of ketosis-prone diabetes. Expert Review of Endocrinology and Metabolism, 2019, 14, 43-48.	1.2	10
30	SYNDROMES OF KETOSIS-PRONE DIABETES. Transactions of the American Clinical and Climatological Association, 2019, 130, 145-155.	0.9	1
31	Arginine Metabolism Is Altered in Adults with A-Î²Â+ÂKetosis-Prone Diabetes. Journal of Nutrition, 2018, 148, 185-193.	1.3	16
32	Changes of glucose levels precede dementia in African-Americans with diabetes but not in Caucasians. , 2018, 14, 1572-1579.		5
33	Adipocytes impair efficacy of antiretroviral therapy. Antiviral Research, 2018, 154, 140-148.	1.9	44
34	Elevated unmethylated and methylated insulin DNA are unique markers of A + Î² + ketosis prone diabetes. Journal of Diabetes and Its Complications, 2018, 32, 193-195.	1.2	9
35	Islet autoantibody positivity in overweight and obese adults with type 2 diabetes. Autoimmunity, 2018, 51, 408-416.	1.2	18
36	Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of â€œA+â€•Subtypes of Ketosis-Prone Diabetes. Diabetes Care, 2018, 41, 2637-2640.	4.3	8

#	Article	IF	Citations
37	Effects of visceral adipose tissue reduction on CVD risk factors independent of weight loss: The Look AHEAD study. Endocrine Research, 2017, 42, 86-95.	0.6	3
38	The Malnourished Heart: An Unusual Case of Heart Failure. American Journal of Medicine, 2017, 130, e297-e298.	0.6	3
39	HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRÎ± and PPARÎ± dysregulation: implications for HIV-specific pathogenesis of NAFLD. Scientific Reports, 2017, 7, 13362.	1.6	27
40	Glucose level decline precedes dementia in elderly African Americans with diabetes. Alzheimer's and Dementia, 2017, 13, 111-118.	0.4	16
41	Effectiveness of a Group-Based Culturally Tailored Lifestyle Intervention Program on Changes in Risk Factors for Type 2 Diabetes among Asian Indians in the United States. Journal of Diabetes Research, 2017, 2017, 1-13.	1.0	39
42	Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner. PLoS ONE, 2017, 12, e0174254.	1.1	9
43	A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development. Human Molecular Genetics, 2016, 25, 3446-3453.	1.4	90
44	Pyruvate Dehydrogenase Activity Is Decreased in Emergency Department Patients With Diabetic Ketoacidosis. Academic Emergency Medicine, 2016, 23, 685-689.	0.8	6
45	P3â€368: Decline in Glucose Levels Precedes Dementia in Elderly African Americans with Diabetes. Alzheimer's and Dementia, 2016, 12, P990.	0.4	0
46	Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques. Retrovirology, 2016, 13, 30.	0.9	46
47	Factors associated with early relapse to insulin dependence in unprovoked A-Î²+ ketosis-prone diabetes. Journal of Diabetes and Its Complications, 2015, 29, 918-922.	1.2	16
48	Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. Diabetes Care, 2015, 38, 1544-1550.	4.3	25
49	A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. Physiological Genomics, 2015, 47, 215-224.	1.0	10
50	Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. Aids, 2015, 29, 667-674.	1.0	112
51	Skeletal muscle and organ masses differ in overweight adults with type 2 diabetes. Journal of Applied Physiology, 2014, 117, 377-382.	1.2	18
52	Association ofTCF7L2variation with single islet autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes Research and Care, 2014, 2, e000008.	1.2	31
53	The villain with a thousand faces. Journal of Diabetes and Its Complications, 2014, 28, 434-435.	1.2	0
54	HIV-1 Vpr Induces Adipose Dysfunction in Vivo Through Reciprocal Effects on PPAR/GR Co-Regulation. Science Translational Medicine, 2013, 5, 213ra164.	5.8	60

#	Article	IF	Citations
55	Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: Further evidence for a unique form of Metabolic Syndrome in HIV patients. Metabolism: Clinical and Experimental, 2013, 62, 1014-1020.	1.5	29
56	Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART). BMC Endocrine Disorders, 2013, 13, 13.	0.9	8
57	HIV-1 Vpr Enhances PPARÎ²/Î´-Mediated Transcription, Increases PDK4 Expression, and Reduces PDC Activity. Molecular Endocrinology, 2013, 27, 1564-1576.	3.7	11
58	The Role of the Immune System in Obesity and Insulin Resistance. Journal of Obesity, 2013, 2013, 1-9.	1.1	135
59	Islet-Specific T-Cell Responses and Proinflammatory Monocytes Define Subtypes of Autoantibody-Negative Ketosis-Prone Diabetes. Diabetes Care, 2013, 36, 4098-4103.	4.3	28
60	Pathogenesis of Aâ^'Î²+ Ketosis-Prone Diabetes. Diabetes, 2013, 62, 912-922.	0.3	53
61	Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatric Diabetes, 2013, 14, 333-340.	1.2	33
62	Impaired Lipoprotein Processing in HIV Patients on Antiretroviral Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1714-1721.	1.1	23
63	Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients. Medicine and Science in Sports and Exercise, 2013, 45, 1043-1050.	0.2	21
64	Characteristics Of Patients With Ketosis-Prone Diabetes (Kpd) Presenting With Acute Pancreatitis: Implications For The Natural History And Etiology Of A Kpd Subgroup. Endocrine Practice, 2013, 19, 243-251.	1.1	8
65	Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine, 2012, 41, 1-10.	1.1	67
66	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of â€œHeart Positive,â€•a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
67	Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of â€œA-Î²+â€• ketosis-prone diabetes based on long-term Î²-cell function, human leukocyte antigen class II alleles, and sex predilection. Metabolism: Clinical and Experimental, 2010, 59, 1448-1455.	1.5	46
68	Treatment of dyslipidemia in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2010, 11, 1845-1854.	0.9	7
69	A-Â- Subtype of Ketosis-Prone Diabetes Is Not Predominantly a Monogenic Diabetic Syndrome. Diabetes Care, 2009, 32, 873-877.	4.3	30
70	Special Patient Populations: HIV Patients. , 2009, , 519-529.		1
71	HLA Class II Alleles Specify Phenotypes of Ketosis-Prone Diabetes. Diabetes Care, 2008, 31, 1195-1200.	4.3	20
72	Syndromes of Ketosis-Prone Diabetes Mellitus. Endocrine Reviews, 2008, 29, 292-302.	8.9	151

#	Article	IF	Citations
73	Monocytes stimulate replication of human subcutaneous preadipocytes and reduce adipocyte differentiation. FASEB Journal, 2008, 22, 948.15.	0.2	0
74	Association of Amino-Terminal-Specific Antiglutamate Decarboxylase (GAD65) Autoantibodies with Î²-Cell Functional Reserve and a Milder Clinical Phenotype in Patients with GAD65 Antibodies and Ketosis-Prone Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 462-467.	1.8	24
75	Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E40-E48.	1.8	26
76	Dysregulated Energy Expenditure in HIV-Infected Patients: A Mechanistic Review. Clinical Infectious Diseases, 2007, 44, 1509-1517.	2.9	27
77	HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms. AIDS Research and Therapy, 2007, 4, 14.	0.7	18
78	Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials, 2006, 27, 518-530.	0.8	18
79	Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. American Journal of Clinical Nutrition, 2006, 84, 204-211.	2.2	21
80	Rise of Plasma Ghrelin With Weight Loss is Not Sustained During Weight Maintenance. Obesity, 2006, 14, 1716-1723.	1.5	54
81	Cardiovascular Event Prevention in the Person With Type 2 Diabetes. The Diabetes Educator, 2006, 32, 163S-173S.	2.6	3
82	Accuracy and Predictive Value of Classification Schemes for Ketosis-Prone Diabetes. Diabetes Care, 2006, 29, 2575-2579.	4.3	137
83	Health outcomes beyond glucose control. American Journal of Managed Care, 2006, 12, S382-91.	0.8	1
84	HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution. Research Initiative, Treatment Action: RITA, 2006, 12, 5-11.	0.1	2
85	Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype. Journal of Diabetes and Its Complications, 2005, 19, 313-318.	1.2	22
86	Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. American Journal of Clinical Nutrition, 2005, 81, 1405-1410.	2.2	49
87	Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Current Atherosclerosis Reports, 2004, 6, 173-179.	2.0	18
88	Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of â€˜systemic steatosisâ€™. Current Opinion in Lipidology, 2004, 15, 59-67.	1.2	64
89	Novel syndromes of ketosis-prone diabetes: implications for management and medical economics. Managed Care, 2004, 13, 7-10; discussion 19-21.	0.3	0
90	Ethnic Differences in Â-Cell Functional Reserve and Clinical Features in Patients With Ketosis-Prone Diabetes. Diabetes Care, 2003, 26, 2469-2469.	4.3	18

#	Article	IF	Citations
91	Economic Impact of Diabetic Ketoacidosis in a Multiethnic Indigent Population: Analysis of costs based on the precipitating cause. Diabetes Care, 2003, 26, 1265-1269.	4.3	108
92	Short- and Long-Term Effects of Growth Hormone (GH) Replacement on Protein Metabolism in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5827-5833.	1.8	27
93	Ketosis-Prone Diabetes: Dissection of a Heterogeneous Syndrome Using an Immunogenetic and Î²-Cell Functional Classification, Prospective Analysis, and Clinical Outcomes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5090-5098.	1.8	201
94	Improved Outcomes in Indigent Patients with Ketosis-Prone Diabetes: Effect of a Dedicated Diabetes Treatment Unit. Endocrine Practice, 2003, 9, 26-32.	1.1	32
95	Metabolic basis of HIV-lipodystrophy syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E332-E337.	1.8	119
96	High Frequency of Serious Infections in Patients with Panhypopituitarism: A Case-Control Study. Clinical Infectious Diseases, 2001, 32, 153-158.	2.9	9
97	Myotonic dystrophy protein kinase (DMPK) induces actin cytoskeletal reorganization and apoptotic-like blebbing in lens cells. Cytoskeleton, 2000, 45, 133-148.	4.4	45
98	New Profiles of Diabetic Ketoacidosis. Archives of Internal Medicine, 1999, 159, 2317-22.	4.3	128